Exclusive: ADC startup Mythic recruits Jazz exec to lead company; Dyne’s CEO shuffle
28 Mar 2024
Executive ChangeADC
Mythic Therapeutics has gone more than a year and a half without a CEO.
That’s changing on April 1, as George Eliades will join the Waltham, MA-based antibody-drug conjugate biotech. Eliades is coming from Jazz Pharmaceuticals, where he’s served as senior vice president of corporate development and chief transformation officer for the past three and a half years.
In the interim, Mythic’s CEO duties were shared among chief scientist Brian Fiske, COO Sandra Poole and chief development officer Gilles Gallant, according to a press release.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.